Pharming Group (NASDAQ:PHAR) Sees Strong Trading Volume – Should You Buy?

Pharming Group (NASDAQ:PHAR) saw unusually-high trading volume on Wednesday . Approximately 21,295 shares were traded during mid-day trading, an increase of 418% from the previous session’s volume of 4,108 shares.The stock last traded at $9.53 and had previously closed at $10.01.

Analyst Ratings Changes

PHAR has been the topic of several research reports. Jefferies Financial Group began coverage on Pharming Group in a report on Monday, December 9th. They set a “buy” rating and a $14.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $37.00 price target on shares of Pharming Group in a research note on Tuesday, December 17th. Finally, Oppenheimer reduced their price objective on Pharming Group from $31.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, October 28th.

Pharming Group Stock Down 3.8 %

The company has a quick ratio of 2.76, a current ratio of 3.53 and a debt-to-equity ratio of 0.41. The business’s fifty day moving average price is $8.93 and its 200 day moving average price is $8.41. The firm has a market capitalization of $623.02 million, a PE ratio of -35.33 and a beta of -0.08.

Institutional Investors Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its stake in Pharming Group (NASDAQ:PHAR) by 75.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 41,110 shares of the company’s stock after purchasing an additional 17,675 shares during the period. Silverberg Bernstein Capital Management LLC owned approximately 0.06% of Pharming Group worth $339,000 as of its most recent SEC filing. Institutional investors own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.